«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2020 04

Page:

652-655

Research Field:

Publishing date:

Info

Title:

Advances in research on skin immune related adverse reactions of anti-PD-1/PD-L1 immunological checkpoint antibodies

Author(s):

Hu Qi; Yu Xuefeng; Li Yu; Hu Jiahe; Yang Wei; Liu Ping; Xie Rui; Bai Yuxian

Department of Digestive Internal Medicine,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.

Keywords:

immunological checkpoint antibodies; immunotherapy; PD-1/PD-L1 monoclonal antibody; skin-related adverse reactions

PACS:

R730.51

DOI:

10.3969/j.issn.1672-4992.2020.04.030

Abstract:

With the gradual popularization of immunological checkpoint inhibitors in clinical trials and applications,more and more patients have obtained significant effects from immunotherapy.The anti-programmed death-1 (PD-1) and ligand (PD-1 ligand,PD-L1) immunological checkpoint blockers have been approved by the US Food and Drug Administration (FDA) for melanoma,metastatic squamous non-small cell lung cancer,advanced renal cell carcinoma,head and neck squamous cell carcinoma,urothelial carcinoma,etc.However,PD-1/PD-L1 inhibitors cause immune-related adverse reactions in the skin,digestive tract,liver,endocrine,lungs and other organs.Skin toxicity such as skin rashes£¬vitiligo,dry skin is the most common and earliest adverse reaction.

References:

£Û1£ÝChen DS,Mellman I.Elements of cancer immunity and the cancer-immune set point£ÛJ£Ý.Nature,2017,541(7637):321-330.
£Û2£ÝBai J,Gao Z,Li X,et al.Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade£ÛJ£Ý.Oncotarget,2017,8(66):110693-110707.
£Û3£ÝAlsaab HO,Sau S,Alzhrani R,et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy:Mechanism,combinations,and clinical outcome£ÛJ£Ý.Front Pharmacol,2017(8):561.
£Û4£ÝD'Errico G,Machado HL,Sainz B Jr.A current perspective on cancer immune therapy:Step-by-step approach to constructing the magic bullet£ÛJ£Ý.Clin Transl Med,2017,6(1):3.
£Û5£ÝHassel JC,Heinzerling L,Aberle J,et al.Combined immune checkpoint blockade (anti-PD-1/anti CTLA-4):Evaluation and management of adverse drug reactions£ÛJ£Ý.Cancer Treat Rev,2017(57):36-49.
£Û6£ÝMotzer RJ,Rini BI,McDermott DF,et al.Nivolumab for metastatic renal cell carcinoma£ºResults of a randomized phase II trial£ÛJ£Ý.Clin Oncol£¬2015£¬33£¨13£©£º1430-1437.
£Û7£ÝAssarzadegan N,Montgomery E,Anders RA.Immune checkpoint inhibitor colitis:The flip side of the wonder drugs£ÛJ£Ý.Virchows Arch,2018,472(1):125-133.
£Û8£ÝTeufel A,Zhan T,H¢‰rtel N,et al.Management of immune related adverse events induced by immune checkpoint inhibition£ÛJ£Ý.Cancer Lett,2019(456):80-87.
£Û9£ÝInno A,Metro G,Bironzo P,et al.Pathogenesis,clinical manifestations and management of immune checkpoint inhibitors toxicity£ÛJ£Ý.Tumori,2017,103(5):405-421.
£Û10£ÝAfzal MZ,Mabaera R,Shirai K.Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone£ÛJ£Ý.Immunother Cancer,2018,6(1):13.
£Û11£ÝJ Haanen,F Carbonnel,C Robert,et al.Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up£ÛJ£Ý.Ann Oncol,2017,28(suppl_4):iv119-iv142.
£Û12£ÝCalabrese L,Mariette X.The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy£ÛJ£Ý.Ann Rheum Dis,2018,77 (2):162-164.
£Û13£ÝVinay Mathew Thomas,Poorva Bindal,Swetha Ann Alexander,et al.Nivolumab-induced hepatitis:A rare side effect of an immune check point inhibitor£ÛJ£Ý.Oncol Pharm Pract,2019:1078155219837342.
£Û14£ÝPassat T,Touchefeu Y,Gervois N,et al.Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4,anti-PD-1 and anti-PD-L1 antibodies in cancer treatment£ÛJ£Ý.Bull Cancer,2018,105(11):1033-1041.
£Û15£ÝWeber JS,Hodi FS,Wolchok JD,et al.Safety profile of nivolumab monotherapy:A pooled analysis of patients with advanced melanoma£ÛJ£Ý.Clin Oncol,2017,35(7):785-792.
£Û16£ÝSanchez K,Page DB,Urba W.Immunotherapy toxicities£ÛJ£Ý.Surg Oncol Clin N Am,2019,28(3):387-401.
£Û17£ÝKM Plachouri,E Vryzaki,S Georgiou.Cutaneous adverse events of immune checkpoint inhibitors:A summarized overview£ÛJ£Ý.Curr Drug Saf,2019,14(1):14-20.
£Û18£ÝPorcu M,De Silva P,Solinas C,et al.Immunotherapy associated pulmonary toxicity:Biology behind clinical and radiological features£ÛJ£Ý.Cancers (Basel),2019,11(3):E305.
£Û19£ÝMcDermott DF,Sosman JA,Sznol M,et al.Atelizumab,an antiprogrammed death-ligand 1 antibody,in metastatic renal cell carcinoma:Long term safety,clinical activity,and immune correlates from a phase Ia study£ÛJ£Ý.Clin Oncol,2016(34):833-842.
£Û20£ÝSanlorenzo M,Vujic I,Daud A,et al.Pembrolizumab cutaneous adverse events and their association with disease progression£ÛJ£Ý.JAMA Dermatol,2015(151):1206-1212.
£Û21£ÝFreeman-Keller M,Kim Y,Cronin H,et al.Nivolumab in resected and unresectable metastatic melanoma:Characteristics of immune-related adverse events and association with outcomes£ÛJ£Ý.Clin Cancer Res,2016(22):886-894.
£Û22£ÝHua C,Boussemart L,Mateus C,et al.Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab£ÛJ£Ý.JAMA Dermatol,2016(152):45-51.
£Û23£ÝPostow MA,Chesney J,Pavlick AC,et al.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma£ÛJ£Ý.N Engl J Med,2015(372):2006-2017.
£Û24£ÝHaanen JBAG,Carbonnel F,Robert C,et al.Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up£ÛJ£Ý.Ann Oncol,2017,28(suppl_4):iv119-iv142.
£Û25£ÝPlachouri KM,Vryzaki E,Georgiou S.Cutaneous adverse events of immune checkpoint inhibitors:A summarized overview£ÛJ£Ý.Curr Drug Saf,2019,14(1):14-20.
£Û26£ÝSibaud V,Boulinguez S,Pages C,et al.Dermatologic toxicities of immune checkpoint inhibitors£ÛJ£Ý.Ann Dermatol Venereol,2018,145(5):313-330.
£Û27£ÝS Saw,HY Lee,QS Ng.Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients£ÛJ£Ý.Eur J Cancer,2017(81):237-239.
£Û28£ÝSchaberg KB,Novoa RA,Wakelee HA,et al.Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy£ÛJ£Ý.Cutan Pathol,2016(43):339-346.
£Û29£ÝJoseph RW,Cappe LM,Goedjen B,et al.Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy£ÛJ£Ý.Cancer Immunol Res,2015(3):18-22.
£Û30£ÝMatsumara N,Ohtsuka M,Kikuchi N,et al.Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma£ÛJ£Ý.Acta Derm Venereol,2016(96):259-260.
£Û31£ÝOhtsuka M,Miura T,Mori T,et al.Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma£ÛJ£Ý.JAMA Dermatol,2015(151):797-799.
£Û32£ÝTotonchy MB,Ezaldein HH,Ko CJ,et al.Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma£ÛJ£Ý.JAMA Dermatol,2016,152(5):590-592.
£Û33£ÝNaidoo J,Page DB,Li BT,et al.Toxicities of the anti-PD-1 and anti PD-L1 immune checkpoint antibodies£ÛJ£Ý.Ann Oncol,2015(26):2375-2391.
£Û34£ÝTeulings HE,Limpens J,Jansen SN,et al.Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival:A systematic review and Meta-analysis£ÛJ£Ý.Clin Oncol,2015(33):773-781.
£Û35£ÝHopkins AM,Rowland A,Kichenadasee G,et al.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers£ÛJ£Ý.Br J Cancer,2017,117(7):913-920.
£Û36£ÝFujii T,Colen RR,Bilen MA,et al.Incidence of immune-related adverse events and its association with treatment outcomes:The MD Anderson Cancer Center experience£ÛJ£Ý.Invest New Drugs,2018,36(4):638-646.
£Û37£ÝLarkin J,Chiarion-Sileni V,Gonzalez R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma£ÛJ£Ý.N Engl J Med,2015(373):23-34.

Memo

Memo:

¹þ¶û±õÒ½¿Æ´óѧ¸½ÊôÖ×ÁöÒ½Ôº½Ü³öÇàÄêÏîÄ¿£¨±àºÅ£ºJCQN2018-04£©

Common functions

Last Update: 2019-12-26